Cargando…
DCision-making in tumors governs T cell anti-tumor immunity
The exploitation of T cell-based immunotherapies and immune checkpoint blockade for cancer treatment has dramatically shifted oncological treatment paradigms and broadened the horizons of cancer immunology. Dendritic cells have emerged as the critical tailors of T cell immune responses, which initia...
Autores principales: | Alfei, Francesca, Ho, Ping-Chih, Lo, Wan-Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390370/ https://www.ncbi.nlm.nih.gov/pubmed/34290401 http://dx.doi.org/10.1038/s41388-021-01946-8 |
Ejemplares similares
-
Cost Effectiveness of DCISionRT for Guiding Treatment of Ductal Carcinoma in Situ
por: Raldow, Ann C, et al.
Publicado: (2020) -
The Clinical Utility of DCISionRT(®) on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery
por: Shah, Chirag, et al.
Publicado: (2021) -
Estrogen/ER in anti-tumor immunity regulation to tumor cell and tumor microenvironment
por: Wang, Tiecheng, et al.
Publicado: (2021) -
Reprogramming T-Cell Metabolism for Better Anti-Tumor Immunity
por: Ping, Yu, et al.
Publicado: (2022) -
Anti-angiogenesis: making the tumor vulnerable to the immune system
por: Griffioen, Arjan W.
Publicado: (2008)